Here is the skinny on Lilly’s weight loss pill that could be a blockbuster alternative to Ozempic and other GLP-1 diabetes and weight loss drugs

Orforglipron, developed by Eli Lilly, represents a significant advancement in the treatment of obesity and type 2 diabetes. Unlike traditional GLP-1 receptor agonists such as Ozempic, which require injections, orforglipron is a non-peptide, oral medication that offers a convenient alternative for patients seeking effective weight management solutions.

One of the primary benefits of orforglipron is its oral administration, eliminating the need for injections. This feature enhances patient compliance and eliminates the discomfort associated with injectable treatments. Furthermore, orforglipron can be taken without restrictions related to food or water intake, simplifying the medication regimen compared to oral semaglutide, which requires fasting prior to consumption.

…

Related on the SLP

Soaring obesity rates: By 2035, more than half of the world’s 8 billion people are predicted to be obese How 1100 pound woman’s rare genetic disorder helps unravel mystery of obesity

Viewpoint: 4 very real AI doomsday scenarios

After Idaho criminalized abortion providers in 2022, one-third of obstetricians fled. Health care advocates are making rural health the case for repealing the ban

Anti-GMO activists in Pakistan rev up their campaign of dire warnings

The safety profile of orforglipron is consistent with other GLP-1 receptor agonists. Common side effects include gastrointestinal issues such as nausea, diarrhea, and constipation, which typically occur during the initial stages of treatment and often diminish over time . Serious adverse events were rare and comparable to those observed with other medications in the same class.

This is an excerpt. Read the original post here